Antibe Therapeutics Inc.
ATE
Rang în acțiuni
#31915
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Preț acțiune
$0.21483059
Ultima sincronizare: 2024-05-07
Capitalizare de piață
$11.13M
Schimbare (1 zi)
0.34%
Schimbare (1 an)
-0.36%
Țară
CA
Tranzacționează Antibe Therapeutics Inc. (ATE)
Categorie
Healthcare
EPS pentru Antibe Therapeutics Inc. (ATE)
EPS la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Antibe Therapeutics Inc., EPS-ul actual al companiei (TTM) este 0. La sfârșitul anului 2026, compania avea un EPS de 0 egal cu EPS-ului din 2026, care a fost de 0.
Istoricul EPS pentru Antibe Therapeutics Inc. din 2026 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| Nu sunt suficiente date pentru perioada selectată. | ||
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $3.11 | - |
US
|
|
| $3.59 | - |
IE
|
|
| $9.73 | - |
US
|
|
| $2.48 | - |
US
|
|
| - | - |
DE
|
